Episode description

In this episode, host Etienne Nichols is joined by Mark DuVal, President and CEO of DuVal & Associates, and Kathy Herzog, Senior Regulatory, Quality, and Compliance Associate at DuVal & Associates. They delve into the recent FDA proposed rule for wound dressings, addressing the classification and regulatory impacts on medical device manufacturers. The discussion covers the historical context, the potential implications for the industry, and strategies for companies to navigate these changes.

• [00:00] - Introduction to the episode and guests
• [02:15] - Overview of Greenlight Guru's QMS software
• [04:30] - Introduction to the FDA's proposed rule on wound dressings
• [06:00] - Mark DuVal discusses the broad implications of the proposed rule
• [12:45] - Kathy Herzog explains the performance requirements and administrative record
• [22:00] - Discussion on industry response and potential litigation
• [30:30] - Impacts on existing and new products in the market
• [40:20] - Strategies for companies to navigate the proposed changes
• [50:00] - Broader implications for the FDA and potential future regulations
• [60:00] - Final thoughts and ways to stay informed

• "This proposed rule feels like a solution in search of a problem." - Mark DuVal
• "It's unsustainable that small wound dressing manufacturers would have to bear that burden on the back of an individual wound dressing." - Kathy Herzog
• "FDA's move to over-regulate well-settled product categories is deeply concerning." - Mark DuVal

MedTech Trends:

1. The FDA's proposed rule could significantly impact the classification and regulation of wound dressings.
2. There is substantial industry opposition to the proposed rule, with many companies and trade associations voicing their concerns.
3. The broader implications of the FDA's actions suggest a shift towards more aggressive regulatory measures.

Practical Tips:

1. Stay informed about regulatory changes and participate in comment periods to voice concerns.
2. Prepare for potential new testing and data requirements by reviewing current performance testing protocols.
3. Engage with industry groups and legal experts to understand the full impact of proposed regulations.

Future Developments:

1. How will the FDA address industry pushback and potential litigation against the proposed rule?
2. Will there be additional guidance from the FDA to help manufacturers navigate the new requirements?
3. What other product categories might the FDA target for reclassification in the near future?

• Greenlight Guru QMS Software
• FDA Proposed Ruling on Wound Dressings
• DuVal & Associates Client Alert on FDA Proposed Rule
• Alliance of Wound Care Stakeholders
• Washington Legal Foundation
• Connect with Etienne...